{"nctId":"NCT00588406","briefTitle":"Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.","startDateStruct":{"date":"2007-09"},"conditions":["Asthma"],"count":95,"armGroups":[{"label":"B","type":"EXPERIMENTAL","interventionNames":["Drug: Budesonide","Drug: albuterol","Drug: Ipratropium bromide","Drug: Prednisone"]},{"label":"P","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: albuterol","Drug: Ipratropium bromide","Drug: Prednisone"]}],"interventions":[{"name":"Budesonide","otherNames":["Pulmicort Respules"]},{"name":"albuterol","otherNames":["proventil","proair","ventolin","salbutamol"]},{"name":"Ipratropium bromide","otherNames":["Atrovent"]},{"name":"Prednisone","otherNames":["deltasone"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* FEV1\\<50% predicted after bronchodilator therapy, age 18-60, presenting to an emergency department with acute asthma\n\nExclusion Criteria:\n\n* other chronic lung disease, \\>15 pack years smoking","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"FEV1 Percent Predicted","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":"16.8"},{"groupId":"OG001","value":"52.6","spread":"15.8"}]}]}]},{"type":"SECONDARY","title":"Hospitalization","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":[]}}}